Back pain: the most common pain problem in Germany

Chronic back pain permanently affects 15-17% of adults in Germany. It is the most common cause of incapacity for work and one of the most expensive illnesses in the healthcare system. Back pain is pharmacologically complex: nociceptive pain (tissue damage), neuropathic pain (nerve root compression), myofascial pain (muscle tension) and centralized pain (chronification) often overlap.

Cannabis intervenes via several mechanisms simultaneously – which makes it interesting for this complex pain pattern.

Pain mechanisms in back pain and ECS targets

Studies: Cannabis and back pain

Aviram & Samuelly-Leichtag 2017 (J Pain Res): Retrospective study, n=206, chronic pain patients using medical cannabis. 70% reported strong or very strong pain reduction. Back pain was the most common indication.

Ware et al. 2010 (CMAJ): RCT, n=21, neuropathic pain (not only back). Nabilone (synthetic THC) significantly better than placebo for pain intensity and sleep. Shows THC analgesia for neuropathic component.

Beaulieu et al. 2006 (J Rheumatol): Fibromyalgia and back pain often overlap. Nabilone better than amitriptyline for fibromyalgia pain and sleep. Indirectly relevant for chronic back pain with central sensitization.

Overview RCTs 2022 (Cochrane analysis): 16 RCTs on cannabis for chronic pain. Moderate evidence for pain reduction. Back pain-specific subgroup shows consistent, albeit moderate analgesia.

Opioid-saving effect for back pain

Many chronic back pain patients receive opioids – with considerable long-term risks (dependence, tolerance, constipation). Cannabis as an opioid adjuvant:

Reiman et al. 2017 (Cannabis Cannabinoid Res): Survey, n=2897 cannabis dispensary patients. 97% of patients who had substituted opioids preferred cannabis. 81% reported that cannabis alone was more effective than cannabis + opioid.

Practical recommendation: cannabis for back pain

Acute pain breakthrough: THC 5-10 mg vaporizer (immediate effect) or sublingual

Continuous pain: CBD 100-200 mg daily + THC 2.5-5 mg in the evening (sleep + muscle relaxation)

Topical (local tension): CBD cream/gel directly on pain point – CB2 in muscle and fascia, no systemic effect

Neuropathic component (sciatica): CBD 150-300 mg + beta-caryophyllene-rich terpenes (CB2 agonist)

FAQ: Cannabis for back pain

Summary

Cannabis addresses all four types of pain in chronic back pain: nociceptive (COX-2), neuropathic (TRPV1/CB1), myofascial (muscle relaxation), centralized (supraspinal modulation). Study data: 70 % pain reduction in survey, moderate analgesia in Cochrane analysis. Opioid saving effect clinically significant. Symptomatically effective for intervertebral disc problems, no substitute for causal therapy. Cannabis in neuropathy for the neuropathic component; cannabis in fibromyalgia for centralized pain.

Social anxiety disorder and the ECS

Social anxiety disorder (SAD) is one of the most common anxiety disorders with a lifetime prevalence of 12%. It is characterized by intense anxiety in social situations, fear of negative evaluation and often with avoidance behavior. The ECS modulates via CB1 in the amygdala and prefrontal cortex – precisely the areas of the brain that are over-activated in SAD.

CBD for social anxiety: study overview

Social anxiety is the best clinically studied area of application for CBD in psychiatry:

Bergamaschi et al. 2011 (Neuropsychopharmacol): RCT, n=24, patients with SAD. CBD 600 mg vs. placebo before simulated public speaking (Public Speaking Test – SPST). CBD significantly reduced anxiety, cognitive impairment and discomfort when speaking vs. placebo. Physiological: normalized heart rate increase and blood pressure response.

De Aquino et al. 2020 (Neuropsychopharmacol): Extended SPST design, CBD 300 mg. Confirmed anxiolytic effect; determined U-shaped dose-response curve: 300 mg optimal, 150 mg and 600 mg less effective.

Linares et al. 2019 (Front Pharmacol): Healthy volunteers, sleep + anxiety under stress. CBD 300 mg showed significant anxiolytic effect vs. placebo.

THC for social anxiety: the paradox

While CBD consistently reduces social anxiety, THC is problematic for SAD:
– THC increases anxiety and paranoia in medium to high doses
– Social situations are subjectively perceived as more threatening
– Cannabis users with SAD have a higher risk of panic attacks in groups

Recommendation for SAD: CBD isolate or broad spectrum without THC. Full-spectrum products with THC can worsen SAD symptoms.

Mechanisms of CBD in social anxiety

5-HT1A agonism: CBD activates serotonin 5-HT1A receptors – same mechanism as buspirone (anxiolytic drug). In the hippocampus and dorsal raphe nucleus relevant for social anxiety.

Amygdala modulation: CBD reduces amygdala activation in response to anxiety-inducing stimuli (fMRI study Bhattacharyya et al. 2012). Amygdala hyperactivation is a core finding in SAD.

Hippocampal neurogenesis: Chronic CBD promotes adult neurogenesis in the hippocampus – similar to SSRIs. Long-term anxiolysis through neuroplastic effect.

Practical application: CBD for social anxiety

Situational intake (before social situations):
– CBD 300 mg sublingual, 60-90 minutes beforehand
– Ideal for: Presentations, dating, social events, public speaking

Daily continuous therapy:
– CBD 150-300 mg daily as adjuvant therapy to psychotherapy
– No substitute for CBT (cognitive behavioral therapy) – the gold standard treatment for SAD

FAQ: Cannabis for social anxiety

Summary

CBD for social anxiety disorder is one of the best documented cannabis indications: two RCTs (Bergamaschi 2011, De Aquino 2020) show significant anxiolysis in SAD patients. Optimal dose: 300 mg CBD (U-curve). Mechanism: 5-HT1A agonism + amygdala modulation. THC contraindicated in SAD – exacerbates paranoia. CBD isolate or broad spectrum without THC. Cannabis for anxiety disorder for generalized anxiety; CBD dosing guide for anxiety dosing.

Cannabis and the male hormone system

Testosterone and male fertility are a relevant topic for cannabis users. The endocannabinoid system is directly integrated into the hypothalamic-pituitary-gonadal (HPG) axis, which regulates testosterone and sperm production. CB1 receptors are found in the hypothalamus, pituitary gland and testes.

Effects of THC on male hormones

Study situation: cannabis and testosterone

Kolodny et al. 1974 (NEJM): First large study. Daily cannabis users had significantly lower testosterone levels than non-users. Study with methodological weaknesses; but fundamentally important.

Gundersen et al. 2015 (Am J Epidemiol): n=1215 young Danish men. Weekly cannabis use associated with 28% lower sperm concentration vs. non-users. Daily use + other drug use: up to 52 % reduction.

Hall et al. 2021 (Human Reprod): No statistically significant association between cannabis use and sperm parameters in younger cohort. Conflicting data confirmed.

Current consensus (2024): Moderate, occasional cannabis use probably has minimal effect on fertility. Daily use, especially >10 mg THC/day, is associated with hormonal and sperm changes. Effects are reversible with abstinence.

CB1 on sperm: Direct effect

Sperm cells express CB1 receptors. Anandamide directly modulates the acrosome reaction (necessary for oocyte penetration) and sperm motility:
– Low anandamide levels: stimulating for motility
– High anandamide/THC levels: inhibitory for motility

THC competes with anandamide for CB1 on sperm – direct inhibition of sperm function has been proven.

What does this mean in practical terms for the desire to have children?

If you actively wish to have children:
– Abstinence from cannabis containing THC at least 3 months before the planned attempt to conceive
– Sperm maturation takes 74 days – all sperm produced today will only be ready for ejaculation in 74 days
– CBD: no relevant negative effects on fertility proven

FAQ: Cannabis and testosterone

Summary

THC has negative effects on testosterone (up to -30 %) and sperm parameters with daily use via CB1 in the HPG axis and directly on sperm. Gundersen 2015 shows -28 % sperm concentration with weekly use. All effects reversible after 4-8 weeks (hormones) or 3 months (sperm). If you want to have children: 3 months abstinence. CBD has no relevant negative fertility effects. Tolerance break for abstinence tips; CBD vs. THC for the fundamental difference.

What is cannabis microdosing?

Microdosing means taking cannabis in such low doses that the therapeutic or mood-enhancing effects are noticeable, but there is no perceptible high. For THC, this is typically 1-5 mg per dose. The concept is particularly relevant for:
– Medical users who want to maintain everyday functionality
– People with low THC tolerance
– Anxiety patients for whom high THC doses trigger panic
– Creative work (slight opening of perception without functional impairment)

Biphasic THC effect: less is more

THC shows a classic biphasic dose-response curve – a basic principle of cannabinoid pharmacology:

Low dose (1-5 mg): Anxiolytic, mood enhancing, mildly focusing, analgesic without sedation

Medium dose (10-20 mg): Euphoria, relaxation, hunger, slight time distortion – classic recreational high

High dose (25-50 mg+): paranoia, anxiety, disorientation – especially in beginners or without tolerance

The paradox: if you want to take cannabis for anxiety, you have to dose low. Higher doses worsen anxiety in many cases.

Microdosing protocol according to experience level

CBD microdosing: why even too little is too little

CBD also shows a biphasic dose effect:
– Too low (<10 mg): Often no noticeable effect
– Moderate (30-100 mg): Anxiolytic, anti-inflammatory, sleep-inducing
– High (150-300 mg): Sleep-inducing, antiepileptic (clinically relevant)

For anxiety: at least 25-50 mg CBD daily for consistent effects. Many users take too little (10 mg softgel) and report no effect – this is a dosing issue.

Practical microdosing methods

Vaporizer: Most precise method for THC. Small puff = ~1-2 mg THC, depending on strain. Effect noticeable in seconds, quick adjustment possible.

Sublingual oil: pipette with 1/4 drop of THC oil or precise CBD oil dosage. Good control.

Microdosing capsules: 2.5 mg THC capsules are medically available; simplest form for precise daily dosing.

Tincture: dropwise control; alcohol-based = fastest oral absorption.

FAQ: Cannabis microdosing

Summary

Microdosing utilizes the biphasic THC dose-response: 1-5 mg THC produces therapeutic effects without intoxication. CBD microdosing starts at 25-50 mg daily for measurable anxiolytic effects. Methods: vaporizer (most precise), sublingual oil, capsules. For daily use: cycling (5 days on, 2 days off) for tolerance avoidance. Tolerance break guide; CBD dosage guide for all indications.

ADHD and the endocannabinoid system

Attention deficit hyperactivity disorder (ADHD) is characterized by dysregulation of dopaminergic and noradrenergic systems. The endocannabinoid system directly modulates both neurotransmitter systems – which is why cannabis self-medication is particularly common among ADHD sufferers (studies estimate 20-30% of ADHD adults).

ECS-dopamine connection for ADHD

CB1 receptors are located on presynaptic dopamine neurons in the mesocorticolimbic system – the ADHD-relevant dopamine pathway:
– CB1 activation by endocannabinoids or THC: modulates dopamine release
– Anandamide deficit in ADHD: Several studies show reduced anandamide levels in ADHD sufferers
– Faah gene polymorphisms: Variant FAAH C385A increases anandamide levels and is associated with less impulsive behavior

Study situation: Cannabis and ADHD

THC for ADHD: the paradox

THC can have a paradoxical effect in ADHD – similar to stimulants (Ritalin) in ADHD:
– Low THC doses: dopamine release modulated → some sufferers report focus improvement
– High THC doses: overactivation of CB1 → distraction, lack of concentration, memory impairment

This is the biphasic dose effect: small doses can help, large doses worsen ADHD symptoms.

CBD for ADHD: a less risky approach

CBD has potentially more beneficial properties for ADHD without intoxication:
– Dopamine modulation via FAAH inhibition and anandamide increase
– Anxiolytic: ADHD concomitant anxiety (in 50% of adults with ADHD)
– Sleep improvement: sleep disorders in 75% of ADHD sufferers
– No risk of addiction and tolerance (no CB1 agonism)

Important: CBD is not a substitute for evidence-based ADHD therapy (methylphenidate, amphetamine, behavioral therapy). Clinical RCTs on CBD for ADHD are lacking.

Risks: Cannabis and adolescent ADHD

ADHD is often diagnosed in adolescence. Cannabis in adolescence is particularly risky for ADHD:
– ADHD increases the risk of cannabis addiction by 2-3 times anyway
– Combination: ADHD + early cannabis use → more severe cognitive impairment
– THC disrupts dopamine maturation in the prefrontal cortex up to 25 years of age

FAQ: Cannabis for ADHD

Summary

ADHD and ECS are linked by dopamine modulation: Anandamide deficit in ADHD, CB1 on dopaminergic neurons. Survey evidence for self-medication strong (Cooper 2017), clinical RCTs lacking. THC biphasic: low doses potentially focusing, high doses harmful. CBD for anxiety and sleep in ADHD without intoxication. Adolescents with ADHD are high-risk group for cannabis dependence. Cannabis and adolescents for developmental risks; cannabis dependence for addiction risks.

What is decarboxylation and why is it necessary?

Fresh cannabis flowers contain hardly any THC – instead its precursor THCA (tetrahydrocannabinolic acid). THCA is not psychoactive and hardly binds to CB1 receptors. Only through heat (decarboxylation) is the carboxyl group split off and the active THC released. If you want to use cannabis for edibles, oils or capsules, you must first decarboxylate it.

The chemical reaction: THCA → THC + CO₂ (carboxyl group is split off as carbon dioxide)

The same applies to CBDA → CBD.

Decarboxylation temperatures and time course

Practical decarboxylation in the oven

Step by step:
1. coarsely crush cannabis (do not grind too finely – fine grinding before decarb leads to terpene degradation)
2. place baking paper on baking tray, spread cannabis evenly
3. preheat the oven to 120°C fan oven
4. Bake for 35-40 minutes
5. cannabis looks light brown-beige when ready – darker = too long
6. allow to cool, then grind finely for further processing

Odor note: Decarboxylation has an intense odor. Ventilate well or seal oven with baking paper to reduce odor.

Infusion: butter, oil, alcohol

After decarboxylation, activated THC is infused into a fat solvent (THC is lipophilic):

Cannabutter: 1g decarboxylated cannabis + 100g butter at 60-70°C, stir for 2-3 hours. Strain. THC content: ~50-60% of the THCA content of the flower (losses through process).

Cannabis oil (coconut or olive oil): Same method. Coconut oil has a higher saturated fat content = better THC solution.

Alcohol tincture: Shake high-proof alcohol (90%+) with decarboxylated cannabis for 30 minutes. Strain. Quick method; can be used sublingually.

THCA raw: Does it have advantages?

Interesting: THCA itself is not pharmacologically worthless – it shows:
– Anti-inflammatory effect (PPAR-γ agonism)
– Antiemetic effect in animal models
– Neuroprotective properties (PPARγ)

Raw cannabis juice (cold-press) or THCA crystals are therefore a separate therapeutic form of application without a psychoactive effect.

FAQ: Cannabis decarboxylation

Summary

Decarboxylation converts inactive THCA into active THC through heat (120°C, 35 min) – necessary for edibles, oils and capsules. Optimum: 120°C circulating air for maximum yield with terpene preservation. Then infuse in butter, coconut oil or alcohol. THCA itself has non-psychoactive therapeutic properties. Edibles guide for pharmacokinetics and dosage; consumption form comparison for all ingestion options.

Cannabis and the cardiovascular system

Cannabis has measurable effects on the cardiovascular system – mainly through THC, not CBD. For most healthy adults, these effects are temporary and harmless. However, they can be clinically relevant for people with existing heart disease, high blood pressure or cardiac arrhythmia.

Cardiovascular effects of THC

Study data: Heart attack and cannabis

Mittleman et al. 2001 (Circulation): Case-crossover study, n=3882 myocardial infarction patients. Risk of myocardial infarction in the first hour after cannabis use: 4.8-fold increased vs. non-use. Absolute risk, however, very low in young healthy people; mainly relevant in the case of pre-existing CHD.

Jouanjus et al. 2014 (J Am Heart Assoc): Analysis of 1979 cases from the French pharmacovigilance system. For cannabis-associated heart problems: 85 % male, average age 34 years. Atrial fibrillation and coronary events overrepresented.

Singh et al. 2018 (J Am Coll Cardiol, Review): Chronic use: increased rate of atherosclerosis due to proinflammatory effects of high-dose THC ingestion. Acute effects (tachycardia) in old age or with pre-existing CHD = main risk factor.

CBD and the heart: Rather positive

In contrast to THC, CBD has cardioprotective properties:
– Antiarrhythmic: CBD reduces ischemia-induced arrhythmias in animal models
– Vasodilating: CBD relaxes blood vessels via TRPV1 and NO release → lowers blood pressure
– Anti-inflammatory: Atherosclerosis is driven by inflammation; CBD has an inhibitory effect
– Manseau et al. 2019: CBD (600 mg once) significantly reduced the increase in blood pressure during stress reactions in RCTs

Risk groups: Who should be careful

– People with coronary heart disease (CHD)
– Cardiac arrhythmia (atrial fibrillation)
– Uncontrolled hypertension
– Heart failure
– Elderly patients (>65 years)
– People on heart medication (digoxin, blood thinners, beta-blockers)

FAQ: Cannabis and the heart

Summary

THC increases heart rate by 20-50 bpm and oxygen demand – harmless in healthy boys, clinically relevant in CHD or arrhythmias (4.8-fold increased risk of heart attack in the first hour, Mittleman 2001). CBD, on the other hand, shows cardioprotective properties (antiarrhythmic, antihypertensive). Risk groups: CHD, atrial fibrillation, heart failure, hypertension, cardiac medication. Cannabis and alcohol for further combination risks; cannabis-drug interactions for cardiovascular medications.

Why does cannabis work less after a long time?

Chronic cannabis users notice it: after months or years, the same amount has a less intense effect than at the beginning. This is not a figment of our imagination – it is a neurobiological phenomenon called pharmacodynamic tolerance, which takes place directly at CB1 receptors.

Neurobiology of THC tolerance

Mechanism 1: CB1 desensitization
With sustained CB1 activation by THC, the receptor internalizes – it is relocated from the cell surface to the cell interior (endosomes). Hours without THC: receptor partially returns. Chronic: basal receptor density decreases permanently.

Mechanism 2: CB1 downregulation
Chronic CB1 overactivation reduces the transcription of CB1 receptor genes – less mRNA, less protein, fewer receptors on the cell surface. Particularly pronounced in the cortex, hippocampus and striatum.

Imaging studies: Hirvonen et al. 2012 (Mol Psychiatry) – PET study, n=30. Chronic cannabis users showed 15-20 % lower CB1 receptor density in the cortex vs. non-users. After 4 weeks of abstinence: partial recovery.

Tolerance timeline: How quickly does tolerance build up?

Cannabis withdrawal symptoms during tolerance break

With regular use, withdrawal symptoms can occur if you suddenly stop. These are not life-threatening but are unpleasant:

Common symptoms (days 1-7):
– Sleep disorders, vivid dreams (THC suppresses REM sleep → rebound phenomenon)
– Irritability, mood instability
– Loss of appetite (counter-effect of the munchies mechanism)
– Sweating, slight fever
– Anxiety, inner restlessness

Duration: Acute symptoms 3-7 days. Sleep disturbances up to 3 weeks. Psychological craving longer.

Strategies for a successful tolerance break

Pause completely: Most effective reset. 2-4 weeks is sufficient for most consumers.

CBD during the break: CBD can alleviate withdrawal symptoms (anxiety, sleep) without CB1 activation – no tolerance-building effect. CBD oil 50-100 mg in the evening for sleep; 30-50 mg during the day for anxiety.

Terpenes for sleep: linalool-rich products (aromatic lavender oil), melatonin for REM rebound.

Tolerance break strategy after break: return to lowest effective dose. Limit consumption to 3-4× per week to avoid rapid tolerance build-up again.

FAQ: THC tolerance and tolerance break

Summary

THC tolerance results from CB1 downregulation and desensitization – measurable in PET studies (15-20 % receptor density reduction). Break duration: 2-4 weeks for daily users. Withdrawal symptoms (sleep, irritability, anxiety) 3-7 days, not dangerous. CBD helps to break without building up CB1 tolerance. After reset: low doses, infrequent use for slow tolerance build-up. Cannabis dependence and withdrawal for severe cases; ECS basics for receptor context.

Palliative care: what cannabis can do

Palliative care is about quality of life – not cure. Cannabis has a particularly well-documented role here: pain relief, antiemesis (against nausea), appetite stimulation and sleep improvement are the four central fields of application. Germany has made medicinal cannabis reimbursable for serious illnesses since 2017 – palliative patients are a core target group.

Palliative fields of application with study evidence

Opioid-sparing effect: the most important palliative benefit

Cannabis combined with opioids reduces the need for opioids – this is the most pharmacologically significant palliative benefit:

Johnson et al. 2010 (J Pain Symptom Manage): RCT, n=177 tumor patients with persistent opioid pain. Nabiximols (Sativex) as an add-on significantly better than placebo for pain relief (NRS reduction 3.7 vs. 1.4 points on a 0-10 scale).

Mechnik et al. 2018 (J Pain): Retrospective study, n=274 palliative care patients. Those who used cannabis reduced opioid dose by a median of 44 %. Significant for opioid-associated side effects (constipation, sedation).

Mechanism: Cannabinoids and opioids act synergistically via different receptor systems (CB1 + μ-opioid receptors) on the same pain circuits.

Dronabinol and nabilone: the approved THC preparations

Dronabinol (Marinol, Syndros): Synthetic delta-9-THC; available as a narcotic prescription in Germany; standard indications: Chemotherapy nausea, HIV wasting. 2.5-20 mg/day.

Nabilone (Cesamet): Synthetic THC analog; stronger antiemetic than dronabinol; chemotherapy nausea when other antiemetics fail.

Nabiximols (Sativex): THC:CBD 1:1 oral spray; approved for multiple sclerosis spasticity in Germany; in many countries also for tumor pain (off-label possible in Germany).

Practical palliative dosing

Pain (day): THC 5-10 mg every 6-8 hours orally; or Sativex 2-4 sprays
Nausea: dronabinol 5 mg 1-3h before chemotherapy + 2-4 hours afterwards
Appetite: THC 2.5 mg 30 min before meals
Sleep (night): THC 5-10 mg + CBD 50-100 mg in the evening

FAQ: Cannabis in palliative care

Summary

Cannabis is particularly well documented in palliative care: Level A for chemotherapy nausea (dronabinol approved), Level B for tumor pain (Sativex RCT data), Level B for loss of appetite and sleep. Opioid saving effect of up to 44 % is the most clinically significant benefit. In Germany since 2017 on narcotic prescription with possible SHI reimbursement. Cannabis in cancer for antitumor studies; medical cannabis on prescription for the access route.

The cannabis paradox: Munchies and still slim?

Cannabis increases appetite (munchies) via CB1 activation in the hypothalamus – this is pharmacologically proven. Nevertheless, epidemiological studies consistently show that cannabis users have on average lower BMI values and lower obesity rates than non-users. This paradox has a scientific basis.

Epidemiological data: Consumers and BMI

Mechanisms: Why cannabis use keeps you slim

ECS adaptation and CB1 downregulation: Chronic cannabis use leads to CB1 downregulation in the hypothalamus. Less active CB1 receptors → lower basal appetite and less orexigenic signaling in everyday life despite acute munchies during use.

Adiponectin increase: THC has been shown in studies to increase adiponectin levels – a hormone that increases insulin sensitivity, promotes fat burning and reduces inflammation. Low adiponectin levels are a key feature of obesity and type 2 diabetes.

Gut microbiome modulation: Cannabis favorably alters the intestinal microbiota: increase of Akkermansia muciniphila (associated with lean phenotype) and reduction of Firmicutes/Bacteroidetes ratio. This effect was demonstrated in animal studies (Cluny et al. 2015).

AMPK activation: CBD activates AMPK (AMP-activated protein kinase) – the same mechanism as metformin. AMPK activation increases fatty acid oxidation and inhibits lipid synthesis.

CBD and adipose tissue: Browning of white adipose tissue

White adipose tissue (energy storage) vs. brown adipose tissue (heat production, calorie consumption):

CBD promotes the conversion of white adipose tissue into brown adipose tissue (browning) in cell cultures (Parray & Yun 2016, Mol Cell Biochem). Fatty acid oxidation genes are upregulated and lipogenic genes are downregulated. Clinical human studies do not yet directly confirm this effect, but the mechanism is well documented.

Rimonabant: The CB1 blocker as proof

Rimonabant (Acomplia) was a CB1 antagonist that was approved as a diet pill in Europe from 2006-2009. CB1 blockade led to:
– Significant weight reduction (8-10 % in RCTs)
– Improved insulin sensitivity
– Waist circumference reduction

Rimonabant was re-authorized due to severe psychiatric side effects (depression, suicidal thoughts). But it proved mechanistically: CB1 inhibition = weight reduction. The reverse conclusion – chronic CB1 downregulation by cannabis = similar effect – is pharmacologically plausible.

FAQ: Cannabis and body weight

Summary

The cannabis paradox – munchies but lower BMI – can be explained by ECS mechanisms: CB1 downregulation in chronic use, adiponectin elevation, favorable microbiome effects and CBD-mediated AMPK activation. Epidemiological studies (Smits 2010, Le Strat 2011) show consistently lower obesity rates among consumers. Clinical weight reduction studies with CBD are still lacking. Cannabis in diabetes for metabolic compounds; endocannabinoid system for the basics.